Nivolumab Plus Gemcitabine for Recurrent or Metastatic Nasopharyngeal Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase II Study of Nivolumab Plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11)
Clin. Cancer Res 2022 Jul 12;[EPub Ahead of Print], HA Jung, KU Park, S Cho, J Lim, KW Lee, MH Hong, T Yun, HJ An, WY Park, S Pereira, CY Ock, B KeamFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.